Zacks Research Has Negative Outlook of CRL Q1 Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Stock analysts at Zacks Research decreased their Q1 2025 earnings estimates for Charles River Laboratories International in a research report issued to clients and investors on Wednesday, March 12th. Zacks Research analyst R. Department now anticipates that the medical research company will earn $2.08 per share for the quarter, down from their prior estimate of $3.10. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share. Zacks Research also issued estimates for Charles River Laboratories International’s Q2 2025 earnings at $2.38 EPS, Q3 2025 earnings at $2.51 EPS, Q4 2025 earnings at $2.58 EPS, FY2025 earnings at $9.55 EPS, Q1 2026 earnings at $2.46 EPS, Q2 2026 earnings at $2.66 EPS, Q3 2026 earnings at $2.71 EPS, Q4 2026 earnings at $2.78 EPS and FY2026 earnings at $10.60 EPS.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm’s revenue for the quarter was down 1.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.46 earnings per share.

Several other brokerages have also recently weighed in on CRL. Citigroup raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and upped their price objective for the stock from $155.00 to $175.00 in a research note on Tuesday, March 4th. Redburn Atlantic raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price objective on the stock in a research note on Monday, March 3rd. UBS Group reaffirmed a “neutral” rating and set a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Barclays reduced their target price on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 18th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a research report on Thursday, February 20th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Hold” and an average target price of $198.36.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $171.27 on Monday. The stock has a market cap of $8.76 billion, a P/E ratio of 1,141.78, a PEG ratio of 4.54 and a beta of 1.45. The company’s 50-day simple moving average is $167.74 and its 200 day simple moving average is $184.50. Charles River Laboratories International has a twelve month low of $150.79 and a twelve month high of $274.77. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, CEO James C. Foster acquired 6,075 shares of the company’s stock in a transaction on Thursday, February 20th. The stock was acquired at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the purchase, the chief executive officer now directly owns 183,639 shares of the company’s stock, valued at $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Joseph W. Laplume sold 4,400 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the sale, the executive vice president now owns 20,013 shares of the company’s stock, valued at $3,252,112.50. This trade represents a 18.02 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Charles River Laboratories International

Hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC acquired a new stake in Charles River Laboratories International in the 3rd quarter worth about $601,000. JPMorgan Chase & Co. raised its stake in Charles River Laboratories International by 21.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock worth $95,086,000 after purchasing an additional 85,759 shares in the last quarter. State Street Corp raised its stake in Charles River Laboratories International by 2.0% in the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after purchasing an additional 41,421 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its stake in Charles River Laboratories International by 3.4% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 111,995 shares of the medical research company’s stock worth $22,060,000 after purchasing an additional 3,714 shares in the last quarter. Finally, Janus Henderson Group PLC increased its holdings in Charles River Laboratories International by 7.6% in the 3rd quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company’s stock valued at $9,064,000 after buying an additional 3,268 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).